Galderma Group N risk profile
38 Normal where most of the sector sits
Measured 21 October 2026 from GALD's filed statements. Recomputed nightly.
38 (Normal), driven by Competitive position at 51, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 24 | Normal | Stable | One-year price volatility — 29.8% |
| Operating pressure | 31 | Normal | Easing | Costs outgrowing revenue — -2.0 percentage points |
| Cash conversion | 14 | Contained | Easing | Capital spending against operating cash — 0.13x |
| Leverage and coverage | 37 | Normal | Easing | Interest cover — 6.49x |
| Competitive position | 51 | Elevated | Stable | R&D-intensity gap against peers — -11.8 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Galderma Group N